Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
CRY > SEC Filings for CRY > Form 8-K on 31-Mar-2014All Recent SEC Filings

Show all filings for CRYOLIFE INC

Form 8-K for CRYOLIFE INC


31-Mar-2014

Entry into a Material Definitive Agreement


Item 1.01 Entry into a Material Definitive Agreement.

On March 26, 2014, CryoLife, Inc. ("CryoLife") entered into an exclusive supply and distribution agreement (the "Agreement") with Hancock Jaffe Laboratories, Inc. ("HJL") whereby CryoLife acquired the exclusive, worldwide rights to market, sell, and distribute HJL's ProCol Vascular Bioprosthesis ("ProCol"), which is a natural, biological graft derived from a bovine mesenteric vein that provides vascular access for end-stage renal disease hemodialysis patients. In addition, CryoLife obtained rights of first refusal with respect to offers HJL may receive in the future from third parties regarding the ProCol technology, rights to approximately 4,000 units of ProCol inventory (the "Initial Inventory"), and the right to acquire the ProCol product line from HJL.

The Agreement has an initial term of three years and will automatically renew for two successive one-year terms unless it is terminated at CryoLife's option. The purchase option will become effective March 27, 2016, and remain available to CryoLife during the term of the Agreement.

As part of the transaction, CryoLife agreed to reimburse HJL for up to approximately $2.26 million of HJL's costs to restart, validate, and obtain necessary FDA approvals with respect to its manufacturing facilities, over four consecutive quarters, beginning with the second quarter of 2014, with no more than $650,000 payable in any quarter. As part of its consideration for this reimbursement, CryoLife will own and retain all proceeds from the sale of the Initial Inventory. Profits from CryoLife's sales of ProCol units other than the Initial Inventory will be shared equally by CryoLife and HJL, after taking into account a per-unit transfer price payable to HJL and a per-unit distribution fee payable to CryoLife. The Initial Inventory is comprised of approximately 200 units of existing commercially saleable ProCol inventory, which will be transferred to CryoLife immediately, and approximately 3,800 units that will be produced and transferred to CryoLife following HJL's receipt of FDA approval of HJL's manufacturing facilities, assuming that such approval is obtained.

The Agreement also contains standard representations, warranties, and indemnity provisions as well as provisions addressing the protection of confidential information, trademarks, and patents and intellectual property rights.

CryoLife issued a press release dated March 27, 2014 to announce the execution of the Agreement; the press release is incorporated herein by reference and attached hereto as Exhibit 99.1.

  Add CRY to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for CRY - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.